[1] Oshita KO, Kobayashi T, Tadokoro T, et al. Outcomes and prognostic analysis of surgical resection for oligometastasis from hepatocellular carcinoma[J]. Anticancer Res, 2023, 43(11): 5189-5196. [2] Avanaz A, Adanir H, Kisaoglu A, et al. Evaluation of overall survival and disease-free survival in patients receiving liver transplantation for hepatocellular carcinoma and comparison of living versus deceased donor liver transplants: results of 15 years of experience[J]. Eurasian J Med, 2023, 55(3): 254-258. [3] Zaki P, Chuong MD, Schaub SK, et al. Proton beam therapy and photon-based magnetic resonance image-guided radiation therapy: the next frontiers of radiation therapy for hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2023, 22: 15330338231206335. [4] Ding F, Huang M, Ren P, et al. Quantitative information from gadobenate dimeglumine-enhanced mri can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study[J]. Eur Radiol, 2023. [5] Lim ES, Kim SM, Shin SS, et al. Diagnostic performance of simulated abbreviated mri for early-stage hepatocellular carcinoma screening: a comparison to conventional dynamic contrast-enhanced mri. Taehan Yongsang Uihakhoe Chi[J], 2021, 82(5): 1218-1230. [6] Li L, Su Q, Yang H. Preoperative prediction of microvascular invasion in hepatocellular carcinoma: a radiomic nomogram based on MRI[J]. Clin Radiol, 2022, 77(4): e269-e279. [7] Kuwano A, Tanaka K, Yada M, et al. Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI[J]. Mol Clin Oncol, 2022, 16(2): 53. [8] Rata M, Khan K, Collins DJ, et al. Dce-mri is more sensitive than ivim-dwi for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases[J]. Cancer Imaging, 2021, 21(1): 67. [9] Yang H, Han P, Huang M, et al. The role of gadoxetic acid-enhanced mri features for predicting microvascular invasion in patients with hepatocellular carcinoma[J]. Abdom Radiol (NY), 2022, 47(3): 948-956. [10] Zhao C, Dai H, Shao J, et al. Accuracy of various forms of contrast-enhanced mri for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis[J]. Front Oncol, 2021, 11: 680691. [11] Ricke J, Steffen IG, Bargellini I, et al. Gadoxetic acid-based hepatobiliary mri in hepatocellular carcinoma[J]. JHEP Rep, 2020, 2(6): 100173. [12] Liang J, Li Z, Li J, et al. Application of ivim-dwi in detecting the tumor vasculogenic mimicry under antiangiogenesis combined with oxaliplatin treatment[J]. Front Oncol, 2020, 10: 1376. [13] Yang C, Wei XQ, Zheng J, et al. A correlative study between ivim-dwi parameters and vegf and mmps expression in hepatocellular carcinoma[J]. Quant Imaging Med Surg, 2023, 13(3): 1887-1898. [14] Masokano IB, Liu W, Xie S, et al. The application of texture quantification in hepatocellular carcinoma using CT and MRI: a review of perspectives and challenges[J]. Cancer Imaging, 2020, 20(1): 67. [15] Mao W, Ding X, Ding Y, et al. Does bi-exponential fitting perform better than mono-exponential fitting in ivim-dwi? an assessment of renal pathological injury of iga nephropathy[J]. Curr Med Imaging, 2023. [16] Zaki IH, Shropshire E, Zhang S, et al. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver mri examination with intravenous gadobenate dimeglumine[J]?. Abdom Radiol (NY), 2021, 46(3): 969-978. [17] Syed M, Shah J, Montazeri SA, et al. Analysis of dynamic hepatobiliary contrast-enhanced mri signal intensity after yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma[J]. Abdom Radiol (NY), 2021, 46(5): 2182-2187. [18] Brunsing RL, Fowler KJ, Yokoo T, et al. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI[J]. Hepatoma Res, 2020, 6. [19] Hu Z, Yu N, Wang H, et al. Pre-radiofrequency ablation mri imaging features predict the local tumor progression in hepatocellular carcinoma[J]. Medicine (Baltimore), 2020, 99(52): e23924. [20] Wang Y, Zhang L, Ning J, et al. Preoperative remnant liver function evaluation using a routine clinical dynamic gd-eob-dtpa-enhanced mri protocol in patients with hepatocellular carcinoma[J]. Ann Surg Oncol, 2021, 28(7): 3672-3682. |